The UAE pharmaceutical market is regarded as the most lucrative market in the Middle Eastern region, growing at a double digit rate for the past few years. Growth can be attributed to a number of factors, such as rapidly escalating population, liberal trade policies, and adaptation of international healthcare standards. These factors will enable the UAE pharmaceutical market to grow at a CAGR of around 17% during 2010 - 2013, says our new research report “UAE Healthcare Sector Forecast to 2012”.
Our extensive research on the UAE pharmaceutical industry has found that, there is a strong preference for branded drugs in the UAE as opposed to generic products. The authorities have responded to this by trying to increase the demand for cheaper generic products through a variety of measures, including tight restrictions on advertising of pharmaceutical products and a ban on direct marketing to the consumer. Further, demand in the OTC medicines market is growing faster than demand for prescription drugs. An increasing number of people are therefore, buying products through pharmacies and investors. Private companies are reacting to this demand trend by rolling out more pharmacy stores.
Our team of experts has segmented the healthcare industry into hospital services market, medical services market, and pharmaceutical market. All these sectors have been further segmented to provide exhaustive knowledge of the industry. Most importantly, regulatory environment prevailing in each of the sector has also been covered in the report.
Our report “UAE Healthcare Sector Forecast to 2012” provides thorough analysis of the various segments of the healthcare industry together with the detail study of the investment opportunities in the country. The report has thoroughly examined current market trends; industrial developments, and competitive landscape to enable clients understand the market structure and its progress in coming years. Due consideration has been given to the possible after effects of recession on the industry. It will help clients to have a proper insight of the current and future outlook of the healthcare industry in the UAE.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment